{"filing":{"accession_number":"0001193125-26-274306","cik":"0001612042","ticker":"ASND","company_name":"Ascendis Pharma A/S","form":"6-K","filing_date":"2026-06-17","report_date":null,"primary_document":"d78361d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1612042/000119312526274306/d78361d6k.htm"},"events":[{"id":12419,"run_id":10989,"accession_number":"0001193125-26-274306","anchor_item_number":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"The company completed the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $187.5 million in cash on June 17, 2026. This is a material asset sale generating substantial one-time cash proceeds. While it is a financial transaction, it does not fit the specific categories of debt issuance, dividend distribution, or dilutive issuance; it is best classified as a financial event (asset disposition) that does not fit a named category.","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-06-17","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":9263,"accession_number":"0001193125-26-274306","item_number":null,"item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The company completed the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $187.5 million in cash on June 17, 2026. This is a material asset sale generating substantial one-time cash proceeds. While it is a financial transaction, it does not fit the specific categories of debt issuance, dividend distribution, or dilutive issuance; it is best classified as a financial event (asset disposition) that does not fit a named category.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:48:39.757995+00:00","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-06-17"}]}